Rosuvastatin and progression of atherosclerosis

  title={Rosuvastatin and progression of atherosclerosis},
  author={Stephen J. Nicholls},
  journal={Expert Review of Cardiovascular Therapy},
  pages={925 - 933}
  • S. Nicholls
  • Published 2008
  • Medicine
  • Expert Review of Cardiovascular Therapy
Technological advances in arterial wall imaging have provided the opportunity to evaluate the impact of medical therapies on the progression of atherosclerosis in vivo. Arterial imaging has been extensively utilized to determine the impact of high-dose statin therapy. Using multiple imaging modalities in the carotid and coronary territories, rosuvastatin has been demonstrated to have a beneficial impact across the spectrum of cardiovascular risk. The impact of modifying levels of atherogenic… Expand
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
Large outcomes trials have clearly shown that statin treatments have a favorable benefit/risk profile in a large range of patients at different levels of risk, with the exception of patients with heart failure and those with renal disease undergoing dialysis. Expand
Effects of rosuvastatin combined with probucol on restenosis after percutaneous coronary intervention
Background and aim: Percutaneous coronary intervention (PCI) is widely used for treatment of coronary heart disease, but the incidence of postoperative restenosis is still high. This study aimed toExpand
Coronary risk assessment using traditional risk factors with CT coronary artery calcium scoring in clinical practice
Measurement of the CACS has become an integral part of the clinician's assessment of a patient's CV risk and for guiding preventative therapies and a smartphone “App” makes this quick to obtain and use. Expand
Review on Rosuvastatin
In vivo studies in animals, and in vitro studies in polite animal and human cells have shown rosuvastatin to possess a high uptake into, and property for, action within the liver, the organ for sterol lowering. Expand
Buyang Huanwu Decoction ameliorates atherosclerosis by regulating TGF-β/Smad2 pathway to promote the differentiation of regulatory T cells.
ByHWD regulates TGF-β/Smad2 signaling pathway to promote the peripheral differentiation of Tregs, increase the number of T Regs, restore the immune balance between CD4+T cells, regulate lipid metabolism, inhibit inflammatory reaction and possesses the potential of enhancing plaque stability. Expand
HIIT can be an alternative for MIT training with regard to the reduction of total and visceral body fat, due to shorter exercise time, and becomes an alternative to MIT training regarding body fat reduction. Expand
Scutellarin inhibition of the rosuvastatin uptake in rat hepatocytes and the competition for organic anion transporting polypeptide 1B1 in HEK293T cells
Exposure to scutellarin increases the plasma concentration of rosuvastatin and inhibits the uptake in rat primary hepatocytes and OATP1B1-HEK293T cells, suggesting a drug interaction between scutellerin and rosuventatin and Oatin 1B1 as a potential mechanism. Expand
The Importance of Medicinal Chemistry Knowledge in the Clinical Pharmacist’s Education
  • J. Fernandes
  • Medicine
  • American Journal of Pharmaceutical Education
  • 2018
It is demonstrated how critical clinical decisions can be addressed using medicinal chemistry knowledge, and medicinal chemistry concepts are essential for the education of pharmacy students to explain drug action in general and clinical decisions. Expand


Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Very high-intensity statin therapy using rosuvastatin 40 mg/d achieved an average LDL-C of 60.8 mg/dL and increased HDL-C by 14.7%, resulting in significant regression of atherosclerosis for all 3 prespecified IVUS measures of disease burden. Expand
Effects of Lipid-Lowering by Simvastatin on Human Atherosclerotic Lesions: A Longitudinal Study by High-Resolution, Noninvasive Magnetic Resonance Imaging
It is demonstrated that effective and maintained lipid-lowering therapy by simvastatin is associated with a significant regression of atherosclerotic lesions, and suggests that statins induce vascular remodeling, as manifested by reduced atheosclerotic burden without changes in the lumen. Expand
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
In middle-aged adults with an FRS of less than 10% and evidence of subclinical atherosclerosis, rosuvastatin resulted in statistically significant reductions in the rate of progression of maximum CIMT over 2 years vs placebo. Expand
Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions: Two Years’ Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging
The present study demonstrates that maintained lipid-lowering therapy with simvastatin is associated with significant regression of established atherosclerotic lesions in humans and indicates that lipid- Lowering therapy isassociated with sustained vascular remodeling and emphasize the need for longer-term treatment. Expand
Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial.
Evidence is provided that statin therapy may have a beneficial effect on plaque volume and composition, as assessed by noninvasive MRI, in patients with moderate hypercholesterolemia. Expand
Clinical trial endpoints: angiograms, events, and plaque instability.
To obtain clinical information more quickly and with fewer patients, investigators have conducted trials using surrogate endpoints that examine the effect of treatment on the underlying disease process through measures of atherosclerotic lesion progression and/or regression and new lesion development. Expand
The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events
This long-term follow-up of the Cholesterol Lowering Atherosclerosis Study cohort indicated that progression of coronary artery disease was predictive of coronary events, and the objective was to determine whether carotid arterial intima-media thickness predicts coronary events. Expand
Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease
  • N. Kapur
  • Medicine
  • Expert review of cardiovascular therapy
  • 2007
This review will provide a comprehensive evaluation of the chemistry, clinical efficacy, safety and tolerability of rosuvastatin, and discuss the future role in the management of CHD and atherosclerosis. Expand
Influence of Lipid-Lowering Therapy on the Progression of Coronary Artery Calcification: A Prospective Evaluation
Treatment with the cholesterol synthesis enzyme inhibitor cerivastatin significantly reduces coronary calcium progression in patients with LDL cholesterol >130 mg/dL. Expand
Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden
Rosuvastatin treatment for 24 months to average low-density lipoprotein cholesterol levels well below 70 mg/dL, accompanied by significant increases in high-density lipid cholesterol, produced regression by decreasing percent diameter stenosis and improving minimum lumen diameter as measured by quantitative coronary angiography in coronary disease patients. Expand